Jennifer Garson
Medical · Chicago, ILNPI 1396753406
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,326 of the $32,047 with a category attached, or 69.7%. 8 manufacturers reported payments, led by Ipsen Biopharmaceuticals, Inc at 57.9% of the total. Among medical clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 55 payments — averaging $582.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Biopharmaceuticals, Inc$19K
- ADC Therapeutics America, Inc.$10K
- Epizyme, Inc.$2K
- Beigene USA, Inc.$780
- CTI Biopharma Corp.$717
- Geron Corporation$613
- plus $58 from 2 others
What the payments were for
- Consulting fees$2,1537%
- Speaking & faculty fees$22,32670%
- Travel & lodging$7,08922%
- Food & beverage$4791%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc | 27 | $18,542 |
| ADC Therapeutics America, Inc. | 19 | $9,697 |
| Epizyme, Inc. | 3 | $1,641 |
| Beigene USA, Inc. | 1 | $780 |
| CTI Biopharma Corp. | 2 | $717 |
| Geron Corporation | 1 | $613 |
| EMD Serono, Inc. | 1 | $37 |
| Bristol Myers Squibb | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,047 in reported general payments places this provider in the 95th percentile of 449 medical providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PromactaEltrombopag Olamine | 27 | $353,034 |
| VenclextaVenetoclax | 19 | $255,500 |
| CalquenceAcalabrutinib Maleate | 16 | $237,790 |
| ImbruvicaIbrutinib | 11 | $169,012 |
| EliquisApixaban | 15 | $9,688 |
| XareltoRivaroxaban | 15 | $9,509 |
| Cyclosporine | 15 | $8,422 |
| Acyclovir | 161 | $1,985 |
| Hydroxyurea | 44 | $900 |
| Potassium Chloride | 19 | $408 |
| Allopurinol | 23 | $136 |
Paid to pharmacies, not to this prescriber.
Other medical in Chicago
- Andrea TurekChicago$145K
- William KvasnickaChicago$19K
- Brittany WolfeChicago$12K
- Eric KingChicago$9K
- Neema ManappuramChicago$8K
- Robert RadtkeChicago$7K
- Koree RamseyChicago$5K
- Justin OkrayChicago$5K
- Alexis DavidmanChicago$5K
- Brittany RankChicago$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.